Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

Exclusion Criteria

• •Disease progression within 3 months of last chemotherapy
• •Prior myeloablative therapies with bone marrow transplantation or peripheral stem cell rescue
• •Platelet count less than 100,000/mm³
• •Hypocellular bone marrow (≤ 15% cellularity)
• •Marked reduction in bone marrow precursors of one or more cell lines
• •History of failed stem cell collection
• •Prior treatment with fludarabine
• •Prior radioimmunotherapy
• •Presence of central nervous system (CNS) lymphoma
• •HIV or AIDS-related lymphoma
• •Evidence of myelodysplasia on bone marrow biopsy
• •Abnormal bone marrow cytogenetics
• •Patients who have received prior external beam radiation therapy to more than 25% of active bone marrow
• •Patients who have received filgrastim
• •Sargramostim therapy within 3 weeks prior to treatment
• •Presence of human anti-mouse antibody (HAMA) reactivity in patients with prior exposure to murine antibodies or proteins
• •Serious nonmalignant disease or infection, which, in the opinion of the investigator and/or sponsor, would compromise other protocol objectives
• •Another primary malignancy (other than squamous cell and basal cell cancer of the skin, in situ carcinoma of the cervix, or treated prostate cancer with stable prostate-specific antigen, PSA) for which the patients has not been disease free for at least 3 years
• •Major surgery, other than diagnostic surgery within 4 weeks
• •Pleural effusion
• •Pregnant
• •Lactating